|
Coronary Arteriosclerosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.
|
30284143 |
2018 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
DDAH1 rs997251 TC + CC genotypes were associated with 2.3-fold higher risk of CAD than TT genotype (p = 0.0063).
|
30284143 |
2018 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease.
|
20167924 |
2010 |
|
Coronary heart disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.
|
30284143 |
2018 |
|
Coronary heart disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the DDAH1 loss-of-function polymorphism is associated with both increased risk of thrombosis stroke and CHD.
|
20167924 |
2010 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
Streptozotocin (STZ) was used to induce diabetes in adult DDAH1 knock-out and wild type mice.Healthy mice served as controls.
|
31818438 |
2019 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our data demonstrated that inducible nitric oxide synthase/gamma-Glutamyl-cysteine ligase (iNOS/GGCL) and DDAH dysregulation may play a key role in high glucose mediated oxidative stress, whereas HO-1 inducers such as CAPE or its more potent derivatives may be useful in diabetes and other stress-induced pathological conditions.
|
31108850 |
2019 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
Innovation and Conclusion: Our results provide the first direct evidence that the DDAH1 has a marked effect on kidney fibrosis and oxidative stress induced by aging or diabetes.
|
28594240 |
2017 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
Innovation and Conclusion: Our results provide the first direct evidence that the DDAH1 has a marked effect on kidney fibrosis and oxidative stress induced by aging or diabetes.
|
28594240 |
2017 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
Streptozotocin (STZ) was used to induce diabetes in adult DDAH1 knock-out and wild type mice.Healthy mice served as controls.
|
31818438 |
2019 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
Our data demonstrated that inducible nitric oxide synthase/gamma-Glutamyl-cysteine ligase (iNOS/GGCL) and DDAH dysregulation may play a key role in high glucose mediated oxidative stress, whereas HO-1 inducers such as CAPE or its more potent derivatives may be useful in diabetes and other stress-induced pathological conditions.
|
31108850 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We found limited evidence that genetic polymorphisms in DDAH genes influence serum ADMA levels in individuals with T1DM.
|
22521321 |
2012 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
From July 2006 to June 2009, we assessed the association between polymorphisms in DDAH1 and type 2 diabetes in 814 consecutive unrelated subjects, including 309 type 2 diabetic patients and 505 non-diabetic individuals.
|
21303562 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine whether serum ADMA levels in type 2 diabetes are influenced by common polymorphisms in the DDAH1 and DDAH2 genes.
|
20209122 |
2010 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We identified that DDAH1: -396_-395insGCGT insertion allele was significantly associated with increased risk of T2DM (discovery: adjusted odds ratio [OR] = 1.380, 95% CI = 1.128-1.687, p = .002; replication: OR = 1.231, 95% CI = 1.007-1.504, p = .043).
|
31733101 |
2020 |
|
Diabetic Cardiomyopathies
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DDAH2 alleviates myocardial fibrosis in diabetic cardiomyopathy through activation of the DDAH/ADMA/NOS/NO pathway in rats.
|
30569164 |
2019 |
|
Diabetic Nephropathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to test the hypothesis that elevation of systemic ADMA levels by knocking out DDAH1 would exacerbate functional and structural glomerular abnormalities in a murine model of diabetic nephropathy.
|
31818438 |
2019 |
|
Diabetic Nephropathy
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis.
|
23147199 |
2012 |
|
Endothelial dysfunction
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
In response to TNF-<i>α</i>, microRNA-21 (miR-21) expression was significantly increased in human umbilical vein endothelial cells (HUVECs), in line with impaired endothelial dysfunction as evidenced by decreased tube formation and migration, endothelial nitric oxide synthase (eNOS) (ser1177) phosphorylation, dimethylarginine dimethylaminohydrolases 1 (DDAH1) expression and metabolic activity, and nitric oxide (NO) concentration as well as increased asymmetric dimethylarginine (ADMA) levels.
|
29682517 |
2018 |
|
Endothelial dysfunction
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Endothelium-specific down-regulation of DDAH1 by miR-21 in hypoxia induced endothelial dysfunction and was prevented by overexpression of DDAH1 and miR-21 blockade.
|
24895913 |
2014 |
|
Endothelial dysfunction
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In this review, the recent advances in the regulation and function of DDAH enzymes, their roles in the regulation of NO generation, and their possible contribution to endothelial dysfunction in patients with cardiovascular and kidney diseases are discussed.
|
17933965 |
2007 |
|
Erectile dysfunction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We aimed to assess whether: 1) ADMA and nitrite levels associated with ED risk and with symptoms intensity; and whether 2) DDAH1 and DDAH2 gene polymorphisms associate with changes in biochemical data, and with ED risk and symptoms intensity.
|
31394201 |
2019 |
|
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we used Ddah1<sup>-/-</sup> mice to investigate the effects of the ADMA/DDAH1 pathway on high-fat diet (HFD)-induced hepatic steatosis.
|
27565538 |
2017 |
|
Fetal Growth Retardation
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Meanwhile, intracellular asymmetric dimethylarginine (ADMA) level was elevated with diminished dimethylarginine dimethylaminohydrolase 1 (DDAH1) expression in IUGR-HUVECs.
|
30392707 |
2018 |
|
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, the results obtained from the study suggest a potentially novel role for the ADMA/DDAH1 signaling pathway in TGF‑β1‑induced HSC activation, and along with the studies of others, suppression of the ADMA/DDAH1 pathway may be an alterative approach for the treatment of liver fibrosis.
|
29207068 |
2018 |